LivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification

Dow Jones11-24

By Chris Wack

LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System.

The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months.

VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures.

The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC.

LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

November 24, 2025 10:47 ET (15:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585495446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 23:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585495446","market":"fut","top_or_hot":-1,"title":"LivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare &amp; Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System. \n</p>\n<p>\n  The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months. \n</p>\n<p>\n  VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures. \n</p>\n<p>\n  The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC. \n</p>\n<p>\n  LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 24, 2025 10:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLivaNova Shares Hit 52-Week High After VNS Therapy Gets Increased Payment Classification\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-24 23:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare &amp; Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System. \n</p>\n<p>\n  The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months. \n</p>\n<p>\n  VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures. \n</p>\n<p>\n  The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC. \n</p>\n<p>\n  LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 24, 2025 10:47 ET (15:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2585495446","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585495446","pubTimestamp":1763999220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System.The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months.VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures.The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC.LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LIVN":"LivaNova PLC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","BK4082":"医疗保健设备"},"translate_title":"VNS疗法提高支付分类后，LivaNova股价触及52周高点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIVN":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  LivaNova shares were trading 9% higher, at $60.52, after the company said the U.S. Centers for Medicare & Medicaid Services assigned VNS Therapy to New Technology Ambulatory Payment Classification 1580 for new patient implants under the 2026 Medicare Hospital Outpatient Prospective Payment System. \n\n\n  The stock hit its 52-week high of $61.48 earlier in the session, and is up 18% in the past 12 months. \n\n\n  VNS Therapy is a LivaNova neuromodulation treatment for patients 4 years of age and older with drug-resistant epilepsy and focal seizures. \n\n\n  The medical technology company said CMS also moved VNS Therapy end-of-service procedures from Level 4 into the Level 5 APC. \n\n\n  LivaNova said that effective Jan. 1, 2026, provider reimbursement for VNS Therapy DRE procedures under Medicare will increase significantly. The changes also significantly reduce a known barrier to procedure penetration as current hospital reimbursement rates for Medicare patients often don't fully cover procedure costs. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 10:47 ET (15:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585495446","isCrawlerRequest":true}